Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension
- First Posted Date
- 2021-11-26
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 47
- Registration Number
- NCT05135000
- Locations
- 🇺🇸
Medical Univ of South Carolina, Charleston, South Carolina, United States
🇺🇸Pulmonary Associates PA, Mesa, Arizona, United States
🇬🇧Novartis Investigative Site, London, United Kingdom
Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer
Phase 3
Active, not recruiting
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2021-11-24
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 96
- Registration Number
- NCT05132075
- Locations
- 🇻🇳
Novartis Investigative Site, Hanoi, Vietnam
🇺🇸Valley Medical Center Research, Renton, Washington, United States
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
Phase 3
Recruiting
- Conditions
- Lupus Nephritis
- Interventions
- First Posted Date
- 2021-11-19
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 420
- Registration Number
- NCT05126277
- Locations
- 🇺🇸
University Of Alabama, Birmingham, Alabama, United States
🇺🇸Wallace Rheumatic Study Center, Los Angeles, California, United States
🇺🇸University of California LA, Los Angeles, California, United States
Biopsy Based Study to Understand Mechanism of Action of Ianalumab in Salivary Glands and Explore Relationships With Clinical Assessments.
- First Posted Date
- 2021-11-18
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 21
- Registration Number
- NCT05124925
- Locations
- 🇫🇷
Novartis Investigative Site, Brest, France
An Observational Prospective Study to Characterize Patients Initiating Enerzair® Breezhaler®, With or Without Sensor, as a Maintenance Treatment for Asthma
Withdrawn
- Conditions
- Asthma
- Interventions
- Other: IND/GLY/MF
- First Posted Date
- 2021-11-16
- Last Posted Date
- 2022-04-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT05120986
Study to Assess the Real World Effectiveness of Inclisiran in Chinese Adult Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
Completed
- Conditions
- Primary HypercholesterolemiaMixed Dyslipidemia
- Interventions
- Other: Inclisiran
- First Posted Date
- 2021-11-11
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 61
- Registration Number
- NCT05118230
- Locations
- 🇨🇳
Novartis Investigative Site, Qionghai, Hainan, China
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan
Phase 2
Recruiting
- Conditions
- Prostate Cancer
- Interventions
- Radiation: 177Lu-PSMA-617Radiation: 68Ga-PSMA-11Other: Best supportive/best standard of care
- First Posted Date
- 2021-11-10
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 110
- Registration Number
- NCT05114746
- Locations
- 🇯🇵
Novartis Investigative Site, Kyoto, Japan
Brolucizumab Treatment Experience Study of Patients With nAMD in UK Routine Clinical Practice
Terminated
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Other: brolucizumab
- First Posted Date
- 2021-11-09
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 302
- Registration Number
- NCT05112835
- Locations
- 🇬🇧
Novartis Investigative Site, Warwick, United Kingdom
Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (Komodo Health)
- First Posted Date
- 2021-11-08
- Last Posted Date
- 2021-12-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 9261
- Registration Number
- NCT05111743
- Locations
- 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States
A Dose Range Finding Study With Open-Label Extension to Evaluate the Safety of Oral LMI070/Branaplam in Early Manifest Huntington's Disease
Phase 2
Terminated
- Conditions
- Early Manifest Huntington Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-11-08
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 26
- Registration Number
- NCT05111249
- Locations
- 🇪🇸
Novartis Investigative Site, Madrid, Spain
© Copyright 2025. All Rights Reserved by MedPath